Larry Corey is the president and director of the Fred Hutchinson Cancer Research Center in Seattle. Previously, he served as head of the University of Washington’s Virology Division and Co-Director of the Fred Hutchinson Cancer Research Center’s Vaccine and Infectious Disease Institute. He is also a Professor of Medicine and Laboratory Medicine at the University of Washington. In 1999, Dr. Corey was selected by the National Institutes of Health to lead the HIV Vaccine Trials Network. Research in Dr. Corey’s laboratories includes studies dealing with the pathogenesis, prevention and treatment of HIV and herpes virus infections. These investigations include development of vaccines for both genital herpes and HIV. His labs have also pioneered novel tests for diagnosing and monitoring therapies for viral infections. In addition, Dr. Corey is an infectious disease attending physician at the Fred Hutchinson Cancer Research Center.
Dr. Corey is a fellow of the Infectious Diseases Society of America and is a member of the American Society for Clinical Investigation, American Epidemiological Society and Association of American Physicians. He is the recipient of the Pan American Society Clinical Virology Award, the American Society for STD Research Parran Award, and the University of Michigan Medical School Distinguished Alumnus Award and the Infectious Diseases Society of America Ender’s Award.
Dr. Corey received his bachelor’s and medical degrees from the University of Michigan in Ann Arbor, MI. He received his infectious diseases training at the University of Washington.
Dr. Corey has authored over 600 publications on infectious disease topics. In addition, as an editorial board member, he has reviewed numerous scientific journals and proceedings.
For us it would be in the area of vaccines first.
The approval of the first cancer therapeutic vaccine from Dendreon in prostate cancer establishes the concept that immunotherapy is a... Read more »
The HIV vaccine field received exciting news Thursday from an HIV vaccine trial conducted in Thailand, where the vaccines tested appeared to reduce the acquisition of HIV by about 30 percent.... Read more »